Christoph Bucher

Christoph is the CMO of Anaveon. Before Christoph was at Roche, where he led the transition to the late-stage development of Crovalimab, a complement C5 inhibitor. Before that, Christoph was at the Novartis Institutes for BioMedical Research, where he led programs in the stem cell transplant and complement system spaces and conducted trials in cell therapy. He obtained his medical degree and training in stem cell transplantation and internal medicine in Basel, and he completed his postdoc in the immunobiology of graft versus host and graft versus leukemia effects in Bruce Blazar’s group at the University of Minnesota. Christoph continues to practice hematology part-time at the University Hospital Basel.